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Abstract.  CIM4 is a broadly distributed cell surface 
glycoprotein expressed in different isoforms in various 
tissues and cell lines.  One of two recently character- 
ized human isoforms, CIM4H, is a cell surface recep- 
tor for hyalumnate,  suggesting a role in the regulation 
of cell-cell and cell-substrate interactions as well as 
of cell migration.  While CD44H has been shown to 
mediate cell adhesion,  direct demonstration that 
CD44H expression promotes cell motility has been 
lacking.  In this work we show that a human melanoma 
cell line,  stably transfected with CIM4H, displays en- 
hanced motility on hyaluronate-coated surfaces while 
transfectants expressing an isoform that does not bind 
hyaluronate,  CD44E, fail to do so. Migration of 
CD44H-expressing transfectants  is observed to be 
blocked by a  soluble CD44-immunoglobulin fusion 
protein as well as by anti-CD44 antibody, and to de- 
pend on the presence of the cytoplasmic domain of 
CD44.  However, cells expressing CIM4H cytoplasmic 
deletion mutants retain significant binding capacity to 
hyaluronate-coated substrate.  Taken together,  our 
results provide direct evidence that CD44H plays a 
major role in regulating cell migration on hyaluronate- 
coated substrate. 
T 
He cell surface glycoprotein CD44 is a polymorphic 
molecule as a result of differential usage of a series of 
exons encoding a portion of the extracellular  domain 
and cell lineage-specific glycosylation (Stamenkovic  et al., 
1991; Brown et al., 1991; Hoffman et al., 1991; Gunthert et 
al.,  1991; Stamenkovic  et al.,  1989). Two human isoforms 
of 85 and 150 kD have recently been characterized.  The 85- 
kD isoform, CD44H, is broadly distributed in hematopoietic 
cells,  fibroblasts,  and  numerous  tumors  of both  mesen- 
chymal  and  neuroectodermal  origin  (Stamenkovic  et al., 
1989; Quackenbush et al.,  1990),  while expression of the 
150-kD  isoform, CD44E, appears restricted to subsets of 
epithelial  cells  (Stamenkovic  et al.,  1991; Brown et al., 
1991). In addition to differences  in  their polypeptide se- 
quences and  posttranslational  modifications,  the  two iso- 
forms  have  been  shown  to  differ  functionally.  Whereas 
CIM4H displays high affinity for hyaluronate  (Aruffo et al., 
1990;  Culty et al.,  1990;  Miyake et al.,  1990;  Sy et al., 
1991),  CD44E  does  not  mediate  attachment  to  surface- 
bound hyaluronate,  and its ligands  remain to be identified 
(Stamenkovic  et al.,  1991; Sy et al.,  1991). 
As  the principal  cell  surface receptor  for hyaluronate, 
CD44H  plays  an  important  role  in  both  cell-cell  and 
cell-substrate adhesion (Stamenkovic et al., 1991; Aruffo et 
al., 1990; Culty et al., 1990; Miyake et al., 1990; Sy et al., 
1991; Miyake et al., 1990b; St. John et al., 1990). However, 
mediating ceil adhesion is likely to be only a part of  the func- 
tion of CD44H. The observations that the cytoplasmic tail 
of CIM4 colocalizes with cytoskeletal proteins (Jacobson et 
al.,  1984a,b; Kalomiris  and Bourguignon,  1989; Lacy and 
Underhill,  1987; Tarone et al.,  1984) and that hyaluronate 
accumulates in areas of cell migration,  including developing 
limb buds (Toole, 1982), and sites of inflammation (Weigel, 
et al.,  1989)  and tumor  invasion  CKnudson et al.,  1984; 
Knudson et al.,  1989;  Knudson and Knudson,  1990),  are 
consistent with the notion that CD44H may play a major role 
in regulation  of cell motility. Although  such a function has 
often been alluded to (Toole, 1982; Ibxley et al., 1991), di- 
rect evidence for a role in motility has been lacking.  To de- 
termine whether expression of either of the two isoforms of 
CD44 influences cell motility, CD44H and CD44E, as well 
as two CD44H cytoplasmic deletion mutants,  were stably 
expressed  in a human CD44-negative melanoma cell line 
and transfectants tested for motility on and adhesion to a va- 
riety  of substrates.  The  choice  of  melanoma  ceils  was 
prompted by observations that melanoma cell invasiveness 
(Hart et al., 1991), metastatic proclivity (Turley and Tretiak, 
1985) and motility  (Thomas,  L.,  and H.R. Byers, unpub- 
lished  observations)  correlate with CD44 expression.  Our 
results show that expression of CD44H promotes melanoma 
cell migration on hyaluronate-coated  surfaces while expres- 
sion of CIM4E has no significant effect. The observed en- 
hancement of ceil migration  is shown to depend on the pres- 
ence of both the extracellular  and the cytoplasmic domain of 
CIM4H, while adhesion  to hyaluronate-coated  substrate is 
predominantly  determined by the extraceUular  domain. 
￿9  The Rockefeller University Press, 0021-9525/92/08/971/7 $2.00 
The Journal of Cell Biology, Volume 118, Number 4, August 1992 971-977  971 Materials and Methods 
cDNA Clones  and Cytoplasmic  Deletion Mutants 
eDNA clones encoding CD44H  (Stamenkovic  et al.,  1989) and CD44E 
(Stamenkovic et al., 1991) were isolated previously and production of solu- 
ble  CD44-immunoglobulin fusions has been  described (Aruffo  et al., 
1990). The cytoplasmic deletion mutants CD44HA1 AND CD44HA2 were 
generated by synthetic oligonucleotide-primed  amplification  of sequences 
encoding the extracellular,  transmembrane, and  truncated  cytoplasmic  do- 
mains of  CD44H in polymerase chain reactions (PCR). A 5'oligonucleotide 
possessing a HindUI endonuclease restriction site was designed as follows: 
CGC GCK} AAG CTT ATG GAC AAG TTT TGG TCK~ CACGCA GCC 
TC~. 
A 3' oligonucleotide  primer complementary to the reverse sequence of 
CD44H starting at residue 297 (CD44HA1) was designed to contain  a stop 
codon  downstream from residue  297  and  an  XhoI endonuclease restriction 
site as follows: CGC GGG CTC GAG TTA CTG CCC ACA CCT TCG ACT 
GTT GAC. 
Similarly, a second 3' oligonucleotide  primer complementary to the re- 
verse sequences  of CD44H starting at residue  305 (CD44HA2) was de- 
signed to contain a stop codon downstream from residue 305 and an XhoI 
restriction site as follows: CGC GGG CTC GAG TTA ACT GTT GAT CAC 
TAG CTT CCC CTT CTG. 
PCR cycles  were conducted along  the following pattern:  94~  min; 
60~  rain; 72"C/3 rain for 30 cycles. Amplified sequences were subjected 
to Hind HI and Xho I digestion and ligated to HindIH/XhoI-cnt  CDM8 vec- 
tor (Seed,  1987). 
Stable Tmnsfectants  and CD44  Expression 
The cell line RPM-MC was derived from a recurrent cutaneous melanoma 
and has been described previously (Byers et ai., 1991). Melanoma cells sta- 
bly expressing CD44 variants were generated by cotrausfecfing the various 
CD44 constructs and the pSV2neo plasmid, bearing the neomycin resis- 
tance gene, by electroporation.  50/~g of plasmid DNA containing a given 
CD44 construct and 1 #g of pSV2Neo DNA were added to 0.4 mi of a 
107/ml cell suspension in PBS in 4-mm electroporation chambers. Cells 
were electroporated at 250 V/960/~F using a Biorad Gene Pulser (Rich- 
mond, CA). Immediately  after electroporation, cells were incubated on ice 
for 10 rain and seeded onto 24-well plates at 2  x  105 cells/well  in DME 
supplemented with 20% FBS (Gibco Laboratories, Grand Island, NY). Af- 
ter 48 h, the medium was replaced with DME/10% FBS contalnln~ 800 
ttg/ml of O418 (Gibco Laboratories). Three to four weeks after transfection 
individual clones were picked,  seeded onto fresh plates, expanded, tested 
for CD44 expression by indirect immunofluorescence,  and subcloned by 
limiting dilution to obtain homogeneous cell lines expressing high levels of 
the various CD44 isoforms and mutants. 
To identify CD44-expressing clones, cells were lifted from plates with 
EDTA and incubated for 45 min at 4~  with the anti-CD44 mAb F10-44-2 
(Accurate Chemicals Corp., Westbury, NY) at a 1:500 dilution. Cells were 
washed in PBS,  incubated with affinity-purified,  fluorescein-conjugated 
goat-antimouse antibody (Cappel, Malvern, PA), washed, and analyzed on 
a FACScan cytometer (Becton Dickinson, Mountainview,  CA). 
Production of  Soluble CD44 
Production of soluble CD44-Ig  and GMPI40-Ig fusion proteins (called 
CD44 or GMP140 receptor globulins [CD44Rg]) has been described previ- 
ously (Aruffo et al.,  1990;  Aruffo et ai.,  1991).  Briefly, CD44-Ig and 
GMPl40-Ig-containinQ  expression vectors were introduced into COS cells 
by the DEAE-Dextran method (Arufo et ai., 1990) and supernatants were 
harvested 5-8 d after transfection. CD44Rg and GMP140Rg were purified 
on  U'isacryl protein  A beads  (Pierce  Chemical  Co.,  Rockford,  IL), dialyzed 
against PBS overnight, and the concentration was determined in an ELISA 
assay. In blocking experiments, purified CD44Rg and GMPl40Rg were 
used at 25 ~,g/ml. 
Attachmen  t Assays 
24-well tissue culture plates (Falcon, Becton-Dickinson, Lincoln Park, NJ) 
were incubated overnight  at 4~  with a 5-mg/ml solution of byahronic acid 
(Sigma Chemical Co.,  St.  Louis, MO) or chondroitin-6-sulfate  (Sigma 
Chemical Co.) in PBS. Wells were washed with PBS, incubated for 12 h 
with heat-denatured BSA (Siema Chemical Co.), washed and used for at- 
tachment experiments.  Control wells were treated with heat-denatured BSA 
only. Subconfluent cultures of CD44 transfectants were radiolabeled with 
3H-thymidine overnight at 37~  detached with EDTA, and seeded at 105 
cells/well.  Cells were allowed to adhere to substrata for 30 rain at 4~  and 
nonadherent cells were washed away with PBS.  These conditions were 
found to produce the least nonspecific  attachment. Adhesion  cells were 
lysed with 0.1% SDS and the corresponding radioactivity was determined. 
The fraction of attached cells for each cell line was deduced by calculating 
the ratio of the radioactivity displayed by attached cells to the radioactivity 
released from the total number of cells initially seeded.  All experiments 
were done in triplicate;  statistical analysis was performed using a t test. 
Attachment Inhibition  Assays 
Hyaluronate-coatecl wells were incubated with CIM4Rg or GMPI40Rg (25 
/~g/mi) for 30 rain at RT before seeding of cell lines, washed with PBS, and 
subjected to seeding with CD44I-I~sh transfectants.  In antibody blocking 
assays, transfectants were preincubated for 30 min at 4~  with anti-CD44 
mAb KM201 (Miyake et ai., 1990), purchased from ATCC or with a con- 
trol, anti-HLA class I mAb, W6/32 (ATCC), before seeding on substrata- 
coated wells.  1 ml of undiluted  hybridoma supernatant was used in each 
case.  Incubation, washing,  and evaluation of attached cells were done as 
above. 
Migration Assays 
Coated substrates were derived following a slight modification of the proce- 
dures of Goodman et ai. (1989).  Briefly, sterile glass coverslips  were in- 
cubatad for 6 h at 4~  in 35-mm petri dishes containing 0.5 or 5 mg/ml 
hyaluronic acid  or  chondroitin  sulfate in PBS. Coverslips were then washed 
with PBS, incubated overnight with heat-denatured BSA, and washed with 
PBS. Control coverslips were treated with heat-denatured BSA only. Sub- 
confluent cnlmres of the various CIM4 transfectants were lifted off culture 
plates with EDTA, and one drop of a suspension of 10  ~ cells was placed 
in  the center of the coated coverslips  immersed in DME/10%FBS gauged 
to obtain a cell density ranging between 0.4 and L0 cells/10a/tm  2. After a 
minimum of 4 h of incubation at 37~  in 5% atmospheric CO2, cell migra- 
tion was studied over a 3-h period under a Nikon Diaphot inverted micro- 
scope with a  10￿  phase-contact objective,  in an attached, hermetically 
sealed  piexiglass  Nikon  NP-2  incubator at  37~  Cell  migration was 
recorded using a Dage-MTl 65DX video camera and a Hitachi TLC1550 
time-lapse video cassette recorder.  Image analysis was performed by play- 
ing back video images, digital saving  of  images at 0, 1, 2, and 3 h, and planar 
morphnmetry determination of the migration rate.  Migration rate was 
defined  by  the  algebraic  sum  of  all  the  two-dimensional  migration  distances 
and  expressed  in  ttm/h.  Migration  of  at  least  35  cells  was  analyzed  for  each 
experimental condition. Image analysis was performed with a Micmcomp 
image analysis system (Southern Micro Instruments, Atlanta, GA), a Nu- 
monic digitablet, a high resolution video monitor (Sony, New York, NY) 
and an IBM-compatible computer (Samsung $500) equipped with a video 
card (PC version plus frame grabber; Imaging Technology, Woburn, MA). 
Data were saved as an MS-DOS (Microsoft)  file and translated through a 
network (TOPS,  Sun Microsystem Co., Berkeley, CA) to a Macintosh SE 
for statistical analysis using a t test. Normalized migration paths were ob- 
tained, using graphic computer software, by "grabbing"  individual cell paths 
and "dragging  ~ them without rotation so that the origin of each path was su- 
perimposed on one central point. 
Migration Inhibition Assays 
Cell suspensions of CD44 Uansfectants were placed on sterile coversllps 
coated with a 5 mg/ml solution of hy~uronic acid as described above. The 
medium was removed, coverslips were washed in PBS, and medium (DME) 
containing 25/~g/ml of CD44Rg, GMPI40Rs, anti-CD44 mAb KM201, or 
anti-HLA mAb (undiluted supernatants) was added to patti dishes contain- 
ing the coverslips.  The preparation was allowed to reequilibrate for 25 rain 
at 37~  followin8 which migration pathways of cells were recorded and 
analyzed as described above. 
Results 
Development of Stable Human Melanoma 
Transfectants Expressing Wild ~  or Truncated 
CD44  Isoforms 
Previously described eDNA clones encoding CD44H (Sta- 
The Journal of Cell Biology, Volume 118, 1992  972 Figure L  CD44  constructs.  Each  of the  constructs  containing 
CD44-~ific eDNA sequences is illustrated sebematieally.  CD44H 
and CD44E represent the entire, unmodified eDNA sequences en- 
coding the 85- and 150-kD isoforms, respectively. The leader pep- 
tide (L), the cartilage link protein-homologous region (CLP), the 
transmembrane region (Tin), and the cytoplasmic domain (cyt) are 
indicated. CD44HA1 is a cytoplasmic deletion mutant lacking the 
entire cytoplasmic domain with the exception of  the six residues in- 
dieated; the asterisk indicates a stop codon. CD44HA2 is a second 
cytoplasmic deletion mutant  containing the first 16 cytoplasmic 
residues. The last six amino acids and the inserted stop codon are 
indicated. CIM4Rg represents the CD44-immunnglobulin fusion 
protein. Antibody exons are boxed and introns are represented by 
connecting lines. H, CH2, and CH3 denote the hinge, and constant 
regions CH2 and CH3 respectively. Amino acid sequences pre- 
dicted at the fusion are indicated below. 
menkovic et al.,  1989) and  CD44E  (Stamenkovic et al., 
1991) as well as two CD44H cytoplasmic deletion mutants, 
CD44HA1 and CIM4HA2, were stably expressed in the hu- 
man melanoma cell line RPM-MC (Byers et al., 1991) which 
does not constitutively express CD44 (Fig.  1).  CIM4HA1 
and two cytoplasmic deletion mutants were derived by syn- 
thetic  oligonucleotide-primed amplification  of eDNA  se- 
quences encoding the entire extraceUular  and transmembrane 
domains and truncated intracytoplasmie segments of  CD44H. 
A stop codon was introduced at the 3' end of  the truncated se- 
quences (Fig. 1), and oligonucleotide primers were designed 
to include restriction sites allowing directional subcloning 
into the CDM8 vector (Seed, 1987). 
Each of the constructs was introduced by electroporation 
into the melanoma cells, eDNA clones were cotransfected 
with pSV2Neo and transfectants were selected for neomycin 
resistance.  Each  of the  resulting  transfectant  clones  was 
Table L  CD44 Expression in Melanoma Cell Transfectants 
Mean fluorescence 
Cell line  Transfected  DNA  intensity 
MC-C  pCDM8 / psv2Neo  3 
MC-44H~h  CD44H / psv2Neo  385 
MC-44H~  CIMAH / psv2Neo  83 
MC-44E  CIMAE / psv2Neo  400 
MC-44HA1  CD44HA1  / psv2Neo  440 
MC-44HA2  CIMAI-IA2  / psv2Neo  375 
Each of the transfectants  used in the present experiments  is indicated, along 
with the transfected  wild type  or mutant  CD44 cDNA (all  eDNA inserts were 
in pCDMS) and the corresponding  level  of surface  expression  as assessed by 
indirect immunofluorescenee.  Reactivity  of CD44 uansfectants was deter- 
mined using  the mAb F-10-44-2  and expressed  as mean  fluorescence  intensity. 
tested for CD44 expression by indirect immunofluorescence 
using the F-10-44-2 anti-CIM4 mAb (Table I), and 5 clones 
were retained for further experiments. The cell line MC-C, 
transfected with the CDM8 and pSV2Neo vectors was used 
as a negative control. It showed no reactivity with anti-CD44 
mAb (mean fluorescence intensity (MFI: 3.0). Two cell lines, 
MC-44I-~.~ and MC44I-I~, transfeeted with CD44H-specific 
eDNA were selected for high (MFI: 385) and low (MFI: 83) 
levels of surface CIM4 expression, respectively, and used to 
determine the role of CD44H in cell motility. To determine 
the requirement for the cytoplasmic  domain of  CD44H in ad- 
hesion and motility, two cell lines,  MC-44HA1  and MC- 
44HA9, expressing cytoplasmic  deletion mutants of  CIM4H, 
were derived.  MC-44HA1  and MC-44HA2  express trun- 
cated forms of  CD44H, containing only the first 6 and 16 cy- 
toplasmic residues, respectively (Fig. I). Both cell lines were 
selected for high expression of  truncated CD44H (respective 
MFIs of  440 and 375), comparable to surface CIM4 expres- 
sion of MC-44H~sh (Table I). A cell line obtained as a result 
of transfection of CD44E, MC-44E, expressing high (MFI: 
400) levels of CD44E was selected for the study of the role 
of CIM4E in cell migration. 
Attachment of CD44H and 
CD44E Melanoma Transfectants to 
Hyaluronate~coated Surfaces 
CD44  transfectants  were radiolabeled with  3H-thymidine 
and tested for attachment to hyaluronate-coated  plates. Cells 
were  seeded  onto plastic  microtiter  wells  coated with  5 
mg/ml hyaluronate, heat-denatured BSA or chondroitin-6- 
sulfate, allowed to attach to substrate for 30 rain, and nonad- 
herent cells removed by washing. Adherent cells were lysed, 
incorporated radioactivity was measured, and the number of 
attached cells calculated from the ratio of residual radioac- 
tivity to radioactivity incorporated by the initial number of 
seeded cells. MC-44H~ ceils displayed 10-fold higher de- 
gree of  attachment to hyaluronate substrates than MC-C con- 
trois while the MC-44E cell line failed to exhibit significant 
binding (Fig.  2). This result confirmed previous observa- 
tions using lymphoma CD44 transfectants (Sy et al., 1991), 
as well as findings that CD44+ but not CIM4- melanomas 
bound hyaluronate-coated substrates (Thomas, L., and H. R. 
Byers, unpublished observations).  Attachment of CD44H 
transfectants  was  effectively blocked by preineubation of 
transfectants with anti-CD44 mAb KM201  (which recog- 
nizes both human and murine CD44) confirming previous 
observations of Miyake et al. (1990), and by preincubating 
hyaluronate-coated wells with CIM4Rg (Fig. 2). 
Migration of CD44H and CD44E Melanoma 
Transfectants on Hyaluronate Substrates 
The principal goal of this study was to determine whether 
the capacity of  CD44H to bind hyaluronate may promote cell 
migration on appropriate substrate.  Migration  rate of the 
different transfectants  on hyaluronate-coated surfaces was 
measured by image analysis after video-microscopic record- 
ing of 3-h migration pathways  (Fig.  3).  Transfectants ex- 
pressing CIM4H or CD44E at different levels were com- 
pared  to  CIM4-negative  MC-C  cells  for  migration  on 
hyaluronate, heat-denatured BSA and chondroitin-6-sulfate- 
1. Abbreviation used in this  paper: MFI, mean fluorescence  intensity. 
Thomas et al. CD44-dependent  Tumor  Cell Migration  973 Figure 2. CD44 transfectant attachment to substrate. Attachment 
is represented as the percentage of seeded cells adhering to sub- 
strate after incubation and removal of nonadherent cells. 10  s ceils 
from each cell line were seeded per well. Substrates are denoted 
by shading: Hyal, hyaluronate; Ch-6-s, Chondroitin-6-sulfate.  All 
experiments were done in triplicate and standard errors are shown. 
coated surfaces. The baseline migration rate of all transfec- 
rants on heat-denatured BSA substrates was statistically ho- 
mogeneous (8.8  +  1.9, 9.4  +  3.7, 10.1 +  2.5,  11.4  +  2.6 
/zm/h for MC-C, MC-I-h,s~, MC-Hto,,  and E, respectively). 
The two CIM4H-expressing cell lines, MC-44I-I~,h (Figs. 3 
and 4) and MC-44H~ (Fig. 4) displayed a significantly in- 
creased migration rate on hyaluronate-coated substrates, and 
the observed increase in motility correlated with the level of 
CD44H  expression  (Fig.  4).  The  migration rate of MC- 
44I-I~,h was 19 5:2.2 and 31.9 +  5.1 #m/h on 0.5 and 5 rag/ 
ml hyaluronate-coated substrates, respectively, compared to 
9.4 +  3,7 (p <  0.001) on heat-denatured BSA, while that of 
MC-44H~,w was  16  +  2.6 and 22.3  +  4.3 ttm/h, respec- 
tively, compared to 10.1 5:2.5 #m/h (p <  0.001) on heat- 
denatured BSA (Fig.  4).  CD44E-expressing  transfeetants 
failed to show any significant increase in migration rate on 
hyaluronate-coated surfaces when compared to BSA-coated 
substrates, and none of the transfectants displayed substan- 
tial acceleration on chondroitin-6-sulfate-coated coverslips 
(Figs. 3 and 4). 
BSA  (control) 
(9.413.7 ~  m/Hr) 
Ch-6-s.  Hyal, Ac.  Hyal. Ac.  Hyal. Ac, 
S  mg/ml  0.5  mg/ml  5  mg/ml  5 mg/ml + CD44 Rg 
(13.0•  g  mlHt)  {~8.9•  g  m:Hr)  ~31.9-tSA g m/Hf)  (10.0•  g  mJHr) 
100 pm 
Figure 3. "Spider" diagram representation of migration pathways 
for 3 h of the MC-44H~k transfectant on different substrates and 
in the presence of soluble CD44. Coating concentrations of sub- 
strate, concentration of soluble CIM4 and migration rate are indi- 
cated. Hyal  Ac, Hyaluronate; Ch-6-s, chondroitin-6-sulfate. 
Figure 4. Migration rate of CD44 transfectants on different sub- 
strates (5 mg/ml coating). Substrates are denoted by shading. Hyal: 
hyaluronate; Ch-6-s, chondroitin-6-sulfate. All experiments were 
done in triplicate and standard errors are shown. 
Migration of  CIM4H Melanoma 
Transfectants Is Blacked by Soluble CIM4Rg and 
Anti-CD44 Antibody 
To further characterize the role of CD44 in cell migration, 
we conducted migration  blocking assays using a soluble form 
of CIM4. The construction of  chimeric CD44-immunoglobu- 
lin cDNA  fusions and subsequent fusion protein produc- 
tion have been described previously (Aruffo, et al.,  1990). 
CD44-Ig  fusion expression  vectors  were  introduced into 
COS cells, and 5-8 d  after transfection, COS cell super- 
natants containing  soluble CD44 (CD44Rg for CD44-recep- 
toglobulin) were harvested. CIM4Rg was purified on protein 
A  columns as previously described (Arutfo et al.,  1990). 
CIM4Rg has been shown to bind hyaluronate in vitro and in 
vivo (Aruffo  et al., 1990). In our blocking experiments, trans- 
fectants were tested for migration on 5 rng/ml hyaluronate- 
coated substrates in the presence of CIM4Rg at a concentra- 
tion of 25 t~g/ml. Transfectants were first allowed to adhere 
to substrates, which were then subjected to incubation with 
CIM4Rg. CD44H-expression-dependent migration on hy~- 
uronate was found to be completely abrogated by the pres- 
ence of CIM4Rg (Figs. 3 and 5). The observed blocking ef- 
fect was most likely the result of CD44Rg interaction with 
surface-bound hyaluronate, rendering it inaccessible to cell 
surface CIM4H. GMP-140Rg  controls (Aruffo et al., 1991) 
failed to  display blocking  (Fig.  5).  Similarly, incubation 
of adherent MC-44H  cells with anti-CIM4 mAb KM201 
(Miyake et  all,  1990)  resulted in  inhibition of migration 
while incubation with an unrelated antibody had no effect 
(Fig. 5). These observations support the notion that CD44H 
plays a direct role in regulating cell migration on hyaluronate- 
associated substrates. 
Migration on but Not Attachment to 
Hyaluronate-associated  Substrate Is Abrogated in 
Melanomas-expressing  CD44H 
Cytoplasmic Mutants 
The observation that CD44  colocalizes with cytoskeletal 
proteins suggests that the presence of the cytoplasmic do- 
main is likely to be required for attachment to and motility 
The Journal  of Cell  Biology,  Volume 118,  1992  9/4 Figure 5. Blocking of migration of CD44H transfectants on hyalu- 
ronate-coated surfaces. Uninhibited migration of CD44H~h on 
hyaluronate-coated  glass slides compared to migration in the pres- 
ence of CD44Rg (25 t~g/ml)  or anti-CD44 mAb KM201 (undiluted 
hybridoma supernatant). GMP140Rg and anti-HLA I mAb were 
used as controls. Baseline migration on heat-denatured BSA is 
shown. All experiments were done in triplicate and standard errors 
are shown. 
on hyaluronate substrates. To test these hypotheses, mela- 
noma cell lines transfected with cytoplasmic deletion mu- 
tants, MC-44HA1 and MC-44HA2, were assayed for attach- 
ment to and migration on hyaluronate-coated surfaces. Both 
cell lines expressed high levels of  truncated CIM4, compara- 
ble  to  those  expressed  by  CD44I-h~sh cells  (Fig.  2).  The 
MC-44HA1 cell line displayed significant attachment to hy- 
aluronate substrates when compared to MC-C and MC-44E 
cells (Fig. 2), although the attachment was lower than that 
of CD44H~sh cells, consistent with the observations of Les- 
ley et al. (1992), suggesting that the presence of  the cytoplas- 
mic domain plays a  role in stabilizing CIM4 interactions 
with substrate. However, neither of the cytoplasmic deletion 
mutants displayed any significant increase in motility on hy- 
aluronate substrates with respect to controls (Fig. 4). 
Discussion 
Earlier work had demonstrated that CD44H is the principal 
cell surface receptor for hyaluronate (Aruffo et al.,  1990; 
Culty et al., 1990;  Miyake et al.,  1990),  and that CIM4H- 
expressing cells adhere to hyaluronate-coated cells and sub- 
strate in vivo and in vitro (Stamenkovic et al.,  1991; Aruffo 
et al.,  1990;  Culty et al,  1990;  Miyake et al.,  1990;  Sy et 
al., 1991; St. John et al., 1990).  The notion that hyaluronate 
creates a low resistance, highly hydrated matrix, and the ob- 
servations that hyaluronate  production is increased at inflam- 
matory sites (Weigel et al., 1989, Hallgren et al., 1990) and 
in areas of tumor invasion (Knudson et ai., 1984; Knudson, 
et al.,  1989;  Knudson and Knudson,  1990;  Toole et al., 
1979)  suggest that CD44-hyaluronate interaction may also 
play a role in regulating cell motility. The present study pro- 
vides direct evidence that expression of CD44H in mela- 
noma cells confers capacity not only for attachment but also 
for motility on hyaluronate substrates. The dual function of 
promoting cell attachment to and motility on substrate may 
help explain the physiologic role of CD44 in the regulation 
of cell  trafficking in tissues as  well as its role  in tumor 
growth. CD44H has been suggested to mediate lymphocyte 
homing to lymphoid tissues (Jalkanen et al.,  1986,  1987). 
Unlike L-selectin (previously called Mel-14/Leu-8/LAM-1), 
which recognizes specific ligands on lymph node high endo- 
thelial venules (Watson et al., 1990), CIM4H displays only 
weak reactivity with high endothelial venules in vivo (Aruffo 
et al., 1990) and does not appear to be necessary for lympho- 
cyte binding to vascular endothelium. However,  expression 
of CIM4H by leukocytes is likely to be required for events 
following endothelial adhesion, including endothelial trans- 
migration, penetration into the extracellular matrix of lym- 
phoid tissue, and subsequent migration to sites of antigen 
presentation. Similarly, leukocytes may depend on CD44H 
expression for efficient  penetration of  inflammatory sites and 
migration  to areas where their effector functions  are required. 
Expression of CD44H is augmented in various types of 
malignancies (Stamenkovic et al., 1989; Stamenkovic et al., 
1991). Melanomas that react with anti-CD44 mAb have been 
observed to express the CD44H  isoform (Stamenkovic et 
al.,  1989;  Starnenkovic et al.,  1991) and display higher at- 
tachment to  and motility on hyaluronate-coated substrate 
than CD44 negative counterparts in vitro (Thomas, L., and 
H. R. Byers, unpublished observations). Human lymphoma 
cells, stably transfected with CD44H, display higher tumori- 
genicity and metastatic proclivity than CD44-negative pa- 
rental  cells  or  CD44E-expressing  transfectants  in  vivo. 
CD44H expression may therefore provide tumor cells of dif- 
ferent origin with a common mechanism for invasion of host 
tissues and formation of foci at secondary sites. Because hy- 
aluronate is not present in free form in the ECM, but is prin- 
cipally bound to proteoglycans and link proteins (Lindahl 
and Hook, 1978),  it may promote development of CIM4H- 
expressing tumors in two ways: by facilitating tumor cell mi- 
gration and tissue penetration and by providing a molecular 
bridge that mediates adhesion of tumor cells to host tissue 
stromal cells and ECM proteoglycans. Tumor cell interaction 
with stromai cells has been shown to stimulate secretion of 
angiogenic factors (West and Kumar, 1989) and hyaluronate 
production (Knudson et al., 1984), while attachment to pro- 
teoglycans may allow tumor cells to gain access to growth 
factors sequestered within the ECM (Ruoslahti, 1989; Ruo- 
slahti and Yamaguchi,  1991). The combined effects on tumor 
cell motility and adhesion of CD44H-hyaluronate interac- 
tion may help explain the high degree of aggressiveness (Sy 
et al.,  1991, Knudson et al.,  1989, Horst et al.,  1990) dis- 
played by tumors expressing elevated levels of CD44H. 
Anti-CIM4 mAbs have been shown to block attachment 
of CIM4H-expressing  cells to hyaluronate (Lesley et al., 
1990;  Miyake et al.,  1990).  In the present study, we used 
anti-CIM4 mAbs and soluble CIM4 Rg in an attempt to in- 
hibit  migration  of  CD44H-expressing  melanoma  cells. 
Migration of CIM4H transfectants was observed to be in- 
hibited  by  the  anti-CIM4  mAb  KM201  which  prevents 
CIM4-hyaluronate interaction (Miyake et ai., 1990).  In ad- 
dition, our results show that soluble CD44,  which reacts 
with hyaluronate in vitro as well as in vivo (Aruffo et al., 
1990), blocks CD44H-transfectant migration on hyaluronate- 
coated surfaces, probably by disrupting cell surface CD44- 
hyaluronate interaction. Taken together, these observations 
add further support to the notion that migration on hyal- 
uronate is promoted by the expression of CIM4H and sug- 
gest that soluble CD44 may provide a valuable tool to study 
tumor cell motility and invasiveness. 
Antibodies to CIM4 have been shown to trigger a variety 
Thomas et al.  CD44-dependent Tumor Cell Migration  975 of  cellular  responses,  including  T cell  activation  (Shimizu ct 
al., 1989; Denning et al., 1990) and monocyte cytokine 
secretion (Webb et al., 1990). These effects  may be ex- 
plained  by signal  transduction  pathways involving  cytoskele- 
tal  proteins  with  which the  cytoplasmic domain of  CD44 has 
been suggested to be associated  (Jacobsen et al., 1984a,b; 
Kalomiris and Bourguignon,  1989; Lacy and Underhill, 
1987; Tarone et  al.,  1984).  Association with the cytoskele- 
ton also  suggests  that  the cytoplasmic domain of  CD44 may 
be  primarily  required  for  promotion of  cell  motility.  This  hy- 
pothesis was verified by observing that melanoma  cells 
transfected  with  CD44H  lacking  the  cytoplasmic domain fail 
to display enhanced  motility on hy~uronate  substrates. 
However, attachment of  these  cells  to hyaluronate  remained 
significant,  although slightly  lower  than that  of  transfcctants 
expressing  wild-type  CD44H, consistent  with  recent  findings 
of Lcsley et al. (1992).  These observations  suggest  that  the 
cytoplasmic domain of  CD44H  is required for cell  motility 
but not for  attachment to substrate  and may have important 
physiologic  implications.  A recent  study  has shown that  acti- 
vation  of  macrophages results  in  dissociation  of  the  cytoplas- 
mic tail  of  CD44 from the  cytoskeleton  (Camp et  al.,  1991). 
Macrophages provide a  good example of  cells  which may bc 
motile  or sessile  depending on  the  function  they  are  required 
to perform. Dissociation of CD44  from the cytoskeleton 
may result  in a reduction or loss  of  cellular  motility  while 
allowing retention  of  significant  substrate-binding  capacity. 
It  is  attractive  to speculate  that  invading tumor cells  having 
penetrated  host  tissue,  may take  advantage era  similar  mech- 
anism to become immobilized and form new colonies.  By 
selectively providing cells with adhesion  and migration 
capability, CD44H  may play a pivotal role in regulating 
cell  trafficking  in  tissues  in  both physiologic  and pathologic 
settings. 
We thank  Terri  Anderson  for  culturing  transfectant  cell  lines  and  evaluating 
CD44 expression. 
This work was supported by National Institutes of Health grants GM- 
43257 and CA-55735  CL Stamenkovic)  and CA-45587 (H.R. Byers).  L. 
Thomas was supported in part by "La Bourse Marc Chaptal de Recherche 
Dermatologique" (France). 
Received for publication  17 February 1992 and in revised  form 11 May 
1992. 
References 
Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill, and B. Seed. 1990. 
CD44  is  the  principal  cell  surface  receptor  for  hyaluronate.  Cell. 
61:1303-1313. 
Aruffu, A., W. Kolanus, G. Walz, P. Fredman, and B. Seed. 1991. CD62/P- 
selectin recognition of myeloid and tumor cell sulfatides.  Cell.  67:35-44. 
Brown, T. A., T. Bouchard, T. St. John, E. Wayne, and W. G. Carter. 1991. 
Human  keratinocytes  express a  new CD44  core protein (CD44E)  as a 
heparan-snifate  intrinsic  membrane proteoglycan with additional exons. J. 
Cell Biol.  113:207-221. 
Byers, H. R., T. Etoh, J. R. Doherty, A. J. Sober, and M. C. Mihm Jr. 1991. 
Cell migration and actin organization  in primary, recurrent cutaneous,  and 
metastatic  melanoma  cell lines. Time lapse and image analysis.  Am.  J. 
Pathol.  139:423-435. 
Camp, R. L., T. A. Kraus, and E. Pare. 1991. Variations in the cytoskeletal 
interaction and posttransiational  modification of the CD44 homing receptor 
in macrophages.  J.  Cell Biol.  115:1283-1292. 
Culty, M., K. Miyake,  P. W. Kincaide,  E. Silorski,  E. Butcher,  and C. Un- 
derhill.  1990. The hyaluronate receptor is a member of the CD44 (H-CAM) 
family of cell surface glycoproteins. J.  Cell Biol.  111:2765-2774. 
Denning, S. M., P. T. Le, K. H. Singer, and B. F. Haynes.  1990. Antibodies 
against the CD44 p80 lymphocyte  homing receptor  molecule  augn~nt human 
peripheral blood T cell activation.  J.  Immunol.  144:7-15. 
Goodman, S. L., G. Risse, and K. Vonder Mark. 1989. The E8 subfragment 
of laminin promotes locomotion of myoblasts over extracellular  matrix. J. 
Cell Biol.  109:799-809. 
Gilnthert,  U., M. Hofmann, W. Rudy, S. Reber, M. Z6ller, L Hanbmann, S. 
Manzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. A new variant of  gly- 
coprotein CD44  confers metastatic  potential  to rat carcinoma  cells. Cell. 
65:13-24. 
Hallgren, R., B. Gerdin, and G. Tufveson.  1990. Hyaluronic acid accumulation 
and redistribution in rejecting rat kidney graft. J. E,  WT. Med.  171:2063-2076. 
Hart, I. R,, M. Birch, and J. F. Marshall.  1991. Cell adhesion receptor expres- 
sion during melanoma progression and metastasis.  Cancer Metastasis Rev. 
10:115-128. 
Hoffmann, M., W. Rudy, M. Zoller, C. Tolg, H, Ponta, P. Herrlich, and U. 
Gunthert.  1991. CD44 splice variants confer metastatic behaviour in rats: 
homologous sequences  are expressed in human tumor cell lines. Cancer Res. 
51:5292-5297. 
Horst, E., C. J. L. M. Meijer, T. Radaszkiewicz,  G. J. Ossekopele, J. H. J. M. 
Van Krieken, and S. Pals.  1990. Adhesion molecules in the prognosis of 
diffuse large cell lymphoma: expression of a lymphocyte homing receptor 
(CD44),  LFA-1 (CD1 la/18), and ICAM-1 (CD54). Leukem/a. 4:595-599. 
Jacobsen, K., D. O'Dell, B. Holifiald, T. L. Murphy, and L T. August.  1984a. 
Redistribution  of a major cell surface glycoproteln during cell movement. 
J.  Cell Biol.  99:1613-1623. 
Jacobsen, K., D.  O'Dell,  and J. T. August.  1984/7. Lateral  diffusion of an 
80,000-dalton  glycoprotein in the plasma membrane of murine fibroblasts: 
relationships  to cell structure  and function. J.  Cell Biol.  99:1624-1633. 
Jalkanen, S., R. F. Bargatze, L. R. Herren, and E. C. Butcher.  1986. Homing 
receptors and the control of  lymphocyte  migration, lmmunol. Rev. 91:39-60. 
Jalkanen, S., R. F. Bargatze, J. de los Toyos, and E. C. Butcher.  1987. Lym- 
phocyte recognition of high endothelium:  antibodies to distinct epitopos of 
an 85-95-kD glycoprotein antigen differentially ialdbit lymphocyte binding 
to  lymph  node,  mucosal,  or  synovial  endothelial  cells.  J.  Cell  Biol. 
105:983-990. 
Kalomiris, E. L., and L. Y. W. Bourguiguom  1989. Lymphoma protein kinase 
C is  associated  with  the transmembrane glycoprotein,  GP85, and may func- 
tion  in GP85-ankyrin binding.  J. Biol.  Chem. 264:8113-8119. 
Knudson, C. B.,  and  W. Knudson. 1990.  Similar  epithelial-stromal  interactions 
in  the  regulation  of  hyaluronate  production  during limb morphogenesis and 
tumor invasion. Cancer Len. 52:113-122. 
Knudson, W., C. Biswas, and B. P. Toole. 1984. Interactions  between human 
tumor cells  and fibroblests  stimulate  hyaluronate synthesis.  Prec. Natl. 
Acad. Sci.  USA. 81:6767-6771. 
Knudson, W., C. Biswes, X. Q. Li, R. E. Nemec, and B. P. Toole. 1989. The 
role and regulation of tumour-nssociatcd hyaluronan. The biology of 
hyaluronan. Ciba Found. Symp. 143:150~169. 
Lacy, B. E., and  C. B. Underhill.  1987.  This hyaluronate  receptor  is  associated 
with actin  filaments.  J. Cell  Biol. 105:1395-1404. 
Lesley,  J.,  R. Schulte,  and R. Hyman. 1990. Binding  of  hyaluronic  acid  to  lym- 
phoid cell  lines  is inhibited  by monoclonal antibodies  against  Pgp-1. Exp. 
Cell  Res. 187:224-233. 
Lcsley,  J., Q. He, K. Miyake, A. Hamann, R. Hyman, and P. W. Kincaide. 
1992.  Requirements for  hyaluronic  acid  binding  by CD44: a role  for  the  cy- 
toplasmic  domain and activation  by antibody.  J. Exp. Med. 175:257-266. 
Lindahl,  U.,  and  M. H{~Sk.  1978.  Olycoseminnglycans and  their  binding  to  bio- 
logical  macromolecules. Annu. Rev.  Biochem. 47:385-417. 
Miyake, K.,  C.  B. Underhill,  J.  Lesley,  and  P.  W. Kincaide. 1990.  Hyaluronate 
can  function as a cell adhesion  molecule  and  CD44  participates in 
hyaluronate recognition.  J. Exp. Med. 172:69-75. 
Quackenbush, E. J.,  S. Vera, A. Greaves, and M. Letarte.  1990. Confirmation 
by peptide  sequence and co-expression  on various  cell  typos  of  the identity 
of CD44 and P85 glycoprotein.  Mol. Immunol. 27:947-955. 
Ruoslahti, E. 1989. Proteoglycans in cell regulation.  J. Biol. Chem. 264: 
13369-13373. 
Ruoslahti,  E.,  and  Y.  Yamaguchi.  1991. Proteoglycans  as modulators  of 
growth factor activities.  Cell.  64:867-869. 
Seed, B. 1987. An LFA-3 eDNA encodes  a phospholipid-linked  membrane pro- 
tein homolng to its receptor CD2. Nature (Lend.). 329:840-842. 
Shimizu, Y., G. A. van Seventer, R. Siraganian,  L. Wahl, and S. Shaw. 1989. 
Dual role of the CD44  molecule in T cell adhesion and activation.  J. Ira- 
manol. 143:2457-2463. 
Stamenkovic, I., M. Amiot, L M. Pesando, and B. Seed. 1989. A lymphocyte 
molecule implicated in lymph node homing is a member of the cartilage link 
protein family.  Cell. 56:1057-1062. 
Stamenkovic, I., A. Aruffo, M. Amiot, and B. Seed. 1991. The hematopoietic 
and epithelial forms of CD44 are distinct polypeptides with different adhe- 
sion potentials  for hyaluronate  bearing cells, EMBO (Eur. Mol.  Biol.  Or- 
gan.) J.  10:343-348. 
St. John, T,, J. Meyer, R. Idzerda, and W.M. Gallatin.  1990. Expression of 
CD44  confers  a  new  adhesive  phenotype  on  transfected  cells.  Cell. 
60:45-52. 
Sy, M. S., Y. J. Guo, and I. Stamenkovic.  1991. Distinct effects of two CD44 
isoform on tumor growth in vivo. J. Exp.  Med.  174:859-866. 
Tarone, G., R. Ferracini,  G. Galetto, and P. Comoglio.  1984. A cell surface 
integral membrane glycoprotein  of  85,000 tool wt (gp85) associated with tri- 
ton X-100-insoluhle  cell cytoske.leton. J.  Cell Biol.  99:512-519. 
Toole, B. P. 1981. Glycosaminoglycans  in morphogenesis. In Cell Biology of 
The Journal  of Cell Biology,  Volume 118,  1992  976 the Extracellular  Matrix.  E. D.  Hay,  editor. Plenum Press, New York. 
259-294. 
Toole, B. P., C. Biswas, and J. Gross. 1979. Hyaluronate  and invasiveness of 
the rabbit V2 carcinoma.  Proc. Natl. Acad. Sci.  USA. 76:6299-6303. 
Turley, E. A., and M. Tretiak.  1985. Glycosaminoglycan production by routine 
melanoma variants  in vivo and in vitro. Cancer Res. 45:5098-5105. 
Tuley, E. A., L. Austen, K. Vandeligt, and C. Clary.  1991. Hyaluronan  and 
cell-associated  hyaluronan  binding protein regulate  the locomotion of ras- 
transformed cells. J.  Cell Biol.  112:1041-1047. 
Watson, S. R., Y. Imal, C. Fennie, J. S. Geoifroy, S. D. Rosen, and L. A. 
Lasky. 1990. A homing receptor-IgG  chimera as a probe for adhesive ligands 
of lymph node high endothelial  venules.  J.  Cell Biol.  110:2221-2229. 
Webb, D. S. A., Y. Shimizu, G. A, Van Seventer, S. Shaw, and T. L. Gerrard. 
1990. LFA-3, CD44 and CD45: physiologic  triggers of human monocyte 
TNF and IL-I release.  Science  (Wash.  DC). 249:1295-1298. 
Weigel, P. H., S. I. Frost, R. D. LeBoeuf,  and C. T. McGary.  1989. The 
specific interaction  between fibrin(ogen)  and hyaluronan:  possible conse- 
quences in haemostasis, inflammation,  and wound healing.  Ciba Found. 
Syrup. 143:248-264. 
West, D. C., and S. Kumar.  1989. Hyaluronan and angiogenesis.  Ciba Found. 
Symp. 143:187-207. 
Thomas et al, CD44.dependent Tumor Cell Migration  977 